Roche will use its diagnostic test for Perjeta and Kadcyla to identify patients best suited for the treatments

Roche ($RHHBY) says it will be pairing a companion diagnostic test that it uses with its breast cancer drug Herceptin to its cancer treatments Perjeta and Kadcyla. It will allow doctors to spot patients who will benefit from those treatments. Kadcyla recently won approval in the EU as a targeted cancer drug for patients with previously treated HER2-positive advanced breast cancer. The FDA signed off on it in February. The FDA last year gave approval to Perjeta for the same condition, but in September it granted it an historic approval to be used ahead of surgery as a breast cancer treatment. Some analysts are predicting mega-status for Perjeta at $8.5 billion in peak sales. Story | More

 

Suggested Articles

If Pfizer wants Lorbrena to be a true follow-up to Xalkori, it has to win a first-line OK in ALK-positive lung cancer. And it just got closer.

Eylea sales dropped 4% to $1.11 billion amid the pandemic, but still beat expectations. And meanwhile, Regeneron's COVID antibody is advancing.

Johnson & Johnson inked a $10-per-dose vaccine supply deal with the U.S. for 100 million initial doses, with 200 million more available down the line.